The stock IMO is now very risky... They have no plan B...
The loss of a timely execution of Femprox, (I think it's dead) and the dusting off of RayVa from the basement have had much to do with why we are now priced in the $1.80s.
Some very smart people like Adam Feuerstein have over the years been highly critical of Vitaros as a product and doubting there is any substantial market for it in a PDE5 dominated world.
This is the bet. Is Vitaros selling and is the sales trajectory upward sloping and to what degree? It's a distraction to be drawn into the debates about Vitaro's effectiveness as a medication or the feedback from patients. While I look for that as much as anyone, at the end of the day it's a business and the business needs revenue and it appears the company is 100% dependent on Vitaros, at least for the next few years to generate cash.
Another poster noted that he believed Pascoe was surprised that the PPS was so low given 3 launches to date.
I'd be surprised if Pascoe was surprised... After all Pascoe just agreed to sell our stock for $1.72 give or take to Aspire. He just expanded our costs by adding another BOD member and oversaw the failed, at least to date attempt to find a partner for Femprox, and to resolve the US rights of Vitaros after communcating to the street that there was movement coming on those fronts. How @#$% surprised can he really be?
The only path forward for the PPS is good sales data on Vitaros and that's very risky. So the discount we are at actually seems fair and again Pascoe thought so to when he sold to Aspire and it's fair to point out there is nothing stopping the BODs or Pascoe from joining us with their own money for a few shares.
The upside is if the sales data is good the rise will be huge.
